Brief: Orthocell Says Application To Market & Sell Remplir In Singapore, Accepted For Review By Health Services Authority Of Singapore
13/02/2024 01:29
Feb 13 (Reuters) - Orthocell Ltd OCC.AX :
* APPLICATION TO MARKET & SELL NERVE REPAIR PRODUCT REMPLIR
IN
SINGAPORE, ACCEPTED FOR REVIEW BY HEALTH SERVICES AUTHORITY OF
SINGAPORE
Source text for Eikon: ID:nASX6N4XP7
Further company coverage: OCC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense